Total Payments
$20,589
2024 Payments
$4,999
Companies
4
Transactions
27
Medicare Patients
341
Medicare Billing
$94,182
Payment Breakdown by Category
Other$7,643 (37.1%)
Research$7,096 (34.5%)
Consulting$3,984 (19.4%)
Travel$1,230 (6.0%)
Food & Beverage$635.50 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7,096 | 14 | 34.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,000 | 1 | 24.3% |
| Consulting Fee | $3,984 | 1 | 19.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,643 | 2 | 12.8% |
| Travel and Lodging | $1,230 | 4 | 6.0% |
| Food and Beverage | $635.50 | 5 | 3.1% |
Payments by Type
General
$13,493
13 transactions
Research
$7,096
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SERVIER PHARMACEUTICALS LLC | $7,642 | 6 | $0 (2024) |
| SERVIER AFFAIRES MEDICALES | $7,096 | 14 | $0 (2023) |
| BTG International, Inc. | $5,666 | 6 | $0 (2019) |
| Agios Pharmaceuticals, Inc. | $184.60 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,999 | 4 | SERVIER PHARMACEUTICALS LLC ($4,999) |
| 2023 | $7,096 | 14 | SERVIER AFFAIRES MEDICALES ($7,096) |
| 2021 | $2,643 | 2 | Servier Pharmaceuticals LLC ($2,643) |
| 2019 | $5,851 | 7 | BTG International, Inc. ($5,666) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $3,984.22 | General |
| 09/20/2024 | SERVIER PHARMACEUTICALS LLC | — | Travel and Lodging | In-kind items and services | $682.94 | General |
| 09/20/2024 | SERVIER PHARMACEUTICALS LLC | — | Food and Beverage | In-kind items and services | $192.66 | General |
| 09/20/2024 | SERVIER PHARMACEUTICALS LLC | — | Food and Beverage | In-kind items and services | $139.18 | General |
| 12/07/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $445.73 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 11/18/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $469.66 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 11/18/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $469.66 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 11/18/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $454.00 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 10/21/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $664.69 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 10/10/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $198.29 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 09/22/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $395.79 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 08/17/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $1,659.35 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 06/09/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $318.97 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 06/09/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $318.97 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 06/09/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $308.33 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 06/04/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $680.41 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 05/10/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $464.90 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 04/06/2023 | SERVIER AFFAIRES MEDICALES | — | — | Cash or cash equivalent | $247.53 | Research |
| Study: STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | ||||||
| 06/15/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | In-kind items and services | $1,023.10 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | In-kind items and services | $1,619.60 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2019 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $184.60 | General |
| 04/18/2019 | BTG International, Inc. | VORAXAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| Category: TOXICITY ANTIDOTE METHOTREXATE TOXICITY | ||||||
| 04/18/2019 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | Cash or cash equivalent | $13.17 | General |
| Category: TOXICITY ANTIDOTE METHOTREXATE TOXICITY | ||||||
| 04/18/2019 | BTG International, Inc. | VORAXAZE (Drug) | Food and Beverage | Cash or cash equivalent | $5.41 | General |
| Category: TOXICITY ANTIDOTE METHOTREXATE TOXICITY | ||||||
| 02/11/2019 | BTG International, Inc. | VORAXAZE (Drug) | Travel and Lodging | In-kind items and services | $307.44 | General |
| Category: TOXICITY ANTIDOTE METHOTREXATE TOXICITY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) | SERVIER AFFAIRES MEDICALES | $7,096 | 14 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 75 | 267 | $130,428 | $23,609 |
| 2022 | 3 | 95 | 314 | $152,596 | $27,290 |
| 2021 | 3 | 80 | 188 | $100,034 | $18,796 |
| 2020 | 5 | 91 | 270 | $142,650 | $24,487 |
Total Patients
341
Total Services
1,039
Medicare Billing
$94,182
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 31 | 98 | $54,354 | $10,138 | 18.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 95 | $43,824 | $8,647 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 32 | 74 | $32,251 | $4,824 | 15.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 35 | 138 | $74,618 | $14,386 | 19.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 126 | $54,913 | $8,981 | 16.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 50 | $23,065 | $3,923 | 17.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 34 | 111 | $60,019 | $12,166 | 20.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 29 | 60 | $26,149 | $4,236 | 16.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $13,866 | $2,394 | 17.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 31 | 108 | $58,088 | $9,023 | 15.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 82 | $37,827 | $6,396 | 16.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 22 | $19,514 | $3,495 | 17.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 13 | 29 | $10,124 | $3,055 | 30.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $9,788 | $1,526 | 15.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 11 | 17 | $7,310 | $992.53 | 13.6% |
About Dr. Joe Mendez, M.D
Dr. Joe Mendez, M.D is a Neurology healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2012. The National Provider Identifier (NPI) number assigned to this provider is 1578819827.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joe Mendez, M.D has received a total of $20,589 in payments from pharmaceutical and medical device companies, with $4,999 received in 2024. These payments were reported across 27 transactions from 4 companies. The most common payment nature is "" ($7,096).
As a Medicare-enrolled provider, Mendez has provided services to 341 Medicare beneficiaries, totaling 1,039 services with total Medicare billing of $94,182. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Neurological Surgery
- Location Salt Lake City, UT
- Active Since 07/24/2012
- Last Updated 11/22/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1578819827
Products in Payments
- VORAXAZE (Drug) $5,666
- TIBSOVO (Drug) $2,643
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Salt Lake City
Dr. Timothy West, Md, MD
Neurology — Payments: $1.0M
Neurology $1.0M
Stacey Steeves, Md, MD
Neurology — Payments: $735,535
Neurology $735,535
Dr. John Foley, M.d, M.D
Neurology — Payments: $345,032
Neurology $345,032
Dr. Amir Arain, Md, MD
Neurology — Payments: $288,901
Neurology $288,901
Mark Bromberg, M.d.,Ph.d, M.D.,PH.D
Neurology — Payments: $252,027
Neurology $252,027
Lucy Dewitt, Md, MD
Neurology — Payments: $126,769
Neurology $126,769